Hypertension

DUBLIN , Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine (TD-9855) in patients with symptomatic neurogenic orthostatic hypotension (nOH). Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic nOH. The Phase 3 study is a four-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety and tolerability of ampreloxetine in approximately 188 patients with symptomatic nOH caused by primary autonomic failure associated with multiple system atrophy (MSA), Parkinson's disease (PD) and pure autonomic failure (PAF). Patients will be randomized to receive a single 10 mg dose of ampreloxetine or placebo once daily for four weeks. The primary...

"These high-functioning legwear products help energize legs, reduce swelling, alleviate achiness and heaviness, and aid in muscle recovery." VIM & VIGR is a line of high-quality compression legwear that combines advanced technology and fashionable designs. Part designer socks, part medical device, VIM & VIGR products are engineered to energize your legs every step of the day and specifically designed to offer support via integrally-knit graduated compression. All of VIM & VIGR’s products are listed with the Food and Drug Administration (FDA) and backed by our 100% Satisfaction Guarantee. Missoula, Mont. - VIM & VIGR, the innovative company known for stylish and functional compression legwear is excited to announce a new partnership with Mr. Checkout. “Compression benefits everyone, but unfortunately many people sacrifice these benefits because of the less than stylish stigma around compression wear,” said Michelle Huie, founder and president of VIM ...

Theravance Biopharma has dosed the first patient in a Phase III clinical trial investigating the efficacy, safety and tolerability of ampreloxetine (TD-9855) for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH). Ampreloxetine is currently being studied as a once-daily norepinephrine reuptake inhibitor (NRI) for use in the treatment of patients with symptomatic nOH, a rare disorder characterised by sustained orthostatic fall in systolic blood pressure (SBP) or diastolic blood pressure (DBP) within three minutes of standing. Theravance aims to enrol around 188 patients for the four-week, multi-centre, randomised, double-blind, placebo-controlled, parallel-group trial. The trial will include patients with symptomatic nOH caused by primary autonomic failure related to multiple system atrophy (MSA), Parkinson’s disease (PD) and pure autonomic failure (PAF). “We recognise a significant opportunity exists for a potentially safe and durable treatment...

http://bit.ly/2UumiL9   DUBLIN , PRNewswire/ --  Theravance Biopharma  Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine (TD-9855) in patients with symptomatic neurogenic orthostatic hypotension (nOH). Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic nOH. The Phase 3 study is a four-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety and tolerability of ampreloxetine in approximately 188 patients with symptomatic nOH caused by primary autonomic failure associated with multiple system atrophy (MSA), Parkinson's disease (PD) and pure autonomic failure (PAF). Patients will be randomized to receive a single 10 mg dose of ampreloxetine or placebo once daily for four we...

About the Author:   Dr. Daniel Yazdi is an Internal Medicine Resident at Brigham and Women’s Hospital/Harvard Medical School interested in the intersection of digital health and clinical medicine. He can be followed on Twitter @DanielYazdi. Watch- ing your blood pressure, pun intended, is about to have a new meaning. Early 2019 marks the release of the first FDA-approved smartwatch blood pressure cuff. Why is this big news? Hypertension affects about  75 million Americans , one out of three adults. It is the leading cause of cardiovascular disease (heart attacks and strokes), resulting in about 1,000 deaths per day. Only 50 percent of patients have their blood pressure adequately managed, demanding a better solution. The watch,  HeartGuide , will be released by Omron. It measures blood pressure by inflating the wrist band; a mechanism similar to that of a traditional cuff. Apple also submitted a  patent  in June 2018 for a similar device,...

Fainting caused by a fall in blood pressure is known as syncope in medical parlance. Its onset is swift and sudden and its duration is short with spontaneous recovery. This press release was orginally distributed by SBWire San Francisco, CA -- ( SBWIRE ) -- 01/23/2019 -- Global Syncope Market: Classification by Type Fainting caused by a fall in blood pressure is known as syncope in medical parlance. Its onset is swift and sudden and its duration is short with spontaneous recovery. Syncope is caused primarily by hypotension. Syncope can be classified into three categories, namely reflex, cardiogenic, and orthostatic hypotension. Among them, cardiogenic or cardiovascular type, also referred to as neurological syncope, is the most common. It is also the most severe form requiring immediate medical attention, especially in the elderly. Orthostatic syncope is characterized by hypotension due to upright position and cerebral hypo perfusion without bradychardia. It results from physical ex...

FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency Details Category: Small Molecules Published on Wednesday, 23 January 2019 11:02 Hits: 162 ROCKVILLE, MD, USA I January 22, 2019 I Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the FDA has accepted its Investigational New Drug (IND) application for CERC-801, an ultra-pure, oral formulation of D-galactose currently in development for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, also known as PGM1-CDG. Peter Greenleaf, CEO stated, “We are in the midst of organizational transformation here at Cerecor into a fully-integrated, innovative biopharmaceutical company.  In less than a year, we have established a commercial footprint, doubled the number of programs in our development pipeline and a...

Orthostatic hypotension is low blood pressure that is experienced when rapidly standing up from a sitting or lying position. Image Credit: Andrey Popov / Shutterstock What is orthostatic hypotension? Orthostatic hypotension, also known as postural hypotension, happens when blood vessels in the body fail to constrict (narrow) in response to gravity. This causes a decrease in blood pressure and reduced blood supply to the brain, leading to lightheadedness and fainting. Clinically, a fall  of 20 mm Hg or more in systolic blood pressure and 10 mm Hg or more in diastolic blood pressure after standing is defined as orthostatic hypotension. Acute or infrequent orthostatic hypotension is generally mild and can be treated easily; however, chronic occurrence likely indicates an underlying disorder. What are the symptoms of orthostatic hypotension? The most common symptom is feeling lightheaded, which usually resolves within a few minutes. However, in severe cases, fainting can occu...

ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the FDA has accepted its Investigational New Drug (IND) application for CERC-801, an ultra-pure, oral formulation of D-galactose currently in development for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, also known as PGM1-CDG. Peter Greenleaf, CEO stated, “We are in the midst of organizational transformation here at Cerecor into a fully-integrated, innovative biopharmaceutical company. In less than a year, we have established a commercial footprint, doubled the number of programs in our development pipeline and achieved several regulatory milestones with the FDA. The FDA’s acceptance of our IND for CERC-801 represents yet another milestone for the organization. We are one step closer to gaining an approval for ...

IndustryResearch.co experts study on “ Global Orthostatic Hypotension Market by Manufacturers, Applications, Types, Regions and Forecast to 2025 ”. This review report furnishes so much reach in attentive with inquiries of market financial gain, development, share, type examination along with applications and areas. the Orthostatic Hypotension business standing, review, bits of information and driving the interest with gifted summary with gauge. This report has been custom-made instrument the market estimate investigation to approve it within the overall Orthostatic Hypotension Market. Summary: Orthostatic hypotension, also known as postural hypotension, is a state of dizziness that is caused due to low blood pressure. This is commonly happen when a person stands up from a long sitting and feel dizziness. Orthostatic hypotension can be caused due to heart problems, dehydration, endocrine problems and nervous system disorders.The orthostatic hypotension disorder is mostly common in...

Gilla ( OTCMKTS:GLLA ) and H. Lundbeck A/S- ( OTCMKTS:HLUYY ) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends. Volatility and Risk Gilla has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500. Comparatively, H. Lundbeck A/S- has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Valuation & Earnings This table compares Gilla and H. Lundbeck A/S-‘s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilla $4.60 million 1.19 -$6.64 million N/A N/A H. Lundbeck A/S- $2.62 billion 3.33 $398.58 million $2.51 17.46 H. Lundbeck A/S- has higher revenue and earnings than Gilla. Profitability This table compares Gi...

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designations (ODD) to Cerecor’s three substrate replacement therapies for Congenital Disorders of Glycosylation (CDGs). The FDA granted ODD to:  CERC-801, D-galactose for the treatment of Phosphoglucomutase 1 (PGM1) Deficiency; CERC-802, D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) Deficiency; and CERC-803, L-fucose for the treatment of Congenital Disorder of Glycosylation IIc (CDG-IIc). Each indication is an ultra-rare CDG estimated to have fewer than 1,000 patients in the United States. All three programs have previously been granted Rare Pediatric Disease Designation (RPDD) by the FDA. Cerecor completed pre-IND meetings with the FDA and se...

Orthostatic Hypotension Market Orthostatic Hypotension Market 2019 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry. Get Sample Copy of this Report@ www.researchreportsworld.com/enquiry/request-sample/13711479 Global Orthostatic Hypotension market 2019 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Orthostatic Hypotension market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report ...

Global Orthostatic Hypotension Market Insights, Forecast To 2025 finds application in numerous products. The report has noticed that the global market is marked by several segments. The Orthostatic Hypotension sector of the global market is complex in nature and depends on demographics. The competitors in the worldwide market are counseled to understand the varied and dynamic supervisory limitations and plot their expansion strategies accordingly. Orthostatic Hypotension Market report represents the current situation of the market based on in-depth analysis of all the major factors that are expected to impact its demand in the near future, it evaluates the state of the market by 2025. The report takes stock of the global market on the basis of its attractiveness as well as investment viability. It also offers quantitative and qualitative analysis of every feature of the market and catches the emerging industry trends. The aim of the report is to allow the readers to concentrate on t...

Orthostatic Hypotension Market Industrial Forecasts on    Orthostatic Hypotension Market:  This Orthostatic Hypotension Market report scrutinizes the various prospects for the shareholder and aspiring market professionals by examining the high-growth segments.  Research Monitor examines each market and its applications, regulatory scenario, technological innovations, market projections, market sizes and shares. The Orthostatic Hypotension Market   report also focuses on the factors such as the increasing awareness among customers about the benefits of the product and development of advanced products those can motivate the market during the forecast period (2019-2025) . To Access PDF Sample Report, With 30 mins free consultation! Click: https://www.reportsmonitor.com/request_sample/287634 The key players covered in this study Mylan Roche Upsher-Smith Laboratories Chelsea Therapeutics Amgen Apotex … Market segment by Type, the product can b...